Calidi biotherapeutic

Recent research from Calidi Biotherapeutics (as of early 2026) highlights a significant shift toward systemic (whole-body) delivery of oncolytic viruses and progress in their stem-cell-based platforms.
Their research and development are currently focused on three primary therapeutic platforms: RedTail, SuperNova, and NeuroNova.
1. RedTail Platform (Lead Candidate: CLD-401)
This is Calidi’s newest and most advanced platform, designed for systemic administration rather than direct injection into a tumor.
* Mechanism: It uses an engineered "enveloped" virus that expresses CD55 on its surface. This acts as a shield, allowing the virus to bypass the patient’s immune system (complement system) and reach metastatic tumor sites through the bloodstream.
* Recent Research (Nov 2025): At the Society for Immunotherapy of Cancer (SITC) 2025 meeting, Calidi presented data showing that CLD-401 can selectively replicate in metastatic tumors and deliver an IL-15 superagonist payload to stimulate a local immune response against the cancer.
* Next Milestone: The company is currently conducting IND-enabling studies and expects to file for human clinical trials by the end of 2026.
2. SuperNova Platform (Candidate: CLD-201)
The SuperNova platform uses allogeneic (off-the-shelf) adipose-derived stem cells to "hide" and deliver oncolytic viruses directly into tumors.
* FDA Breakthrough (July 2025): The FDA granted Fast Track Designation to CLD-201 for the treatment of Soft Tissue Sarcoma.
* Clinical Status: A Phase 1 clinical trial was initiated in 2025 targeting multiple solid tumors, including breast cancer and head and neck squamous cell carcinoma. This trial aims to prove that the stem cell delivery system prevents the virus from being neutralized by the patient's own antibodies.
3. NeuroNova Platform (Candidate: CLD-101)
Focused on high-grade gliomas (brain cancer), this platform uses neural stem cells to deliver an oncolytic adenovirus.
* Clinical Data (2025): Calidi reported interim data from its Phase 1 trials (conducted with partners like City of Hope and Northwestern University). The research indicated that multiple intracerebral doses are safe and feasible, with some patients showing stable disease and a median overall survival of approximately 18.4 months in recurrent glioma cases.
Pipeline Summary at a Glance
| Candidate | Platform | Indication | Status (Early 2026) |
|---|---|---|---|
| CLD-401 | RedTail | Lung, Head & Neck, Metastatic | Pre-clinical; IND filing by end of 2026 |
| CLD-201 | SuperNova | Soft Tissue Sarcoma, Solid Tumors | Phase 1; FDA Fast Track |
| CLD-101 | NeuroNova | High-Grade Glioma | Phase 1b/2 ongoing |
> Key takeaway: Calidi’s current research trajectory is moving away from simple "viral killing" toward using viruses as genetic delivery vehicles that can be injected systemically to find and treat cancer wherever it has spread in the body.